These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 34886719)

  • 1. Predicting Mortality in COPD with Validated and Sensitive Biomarkers; Fibrinogen and Mid-Range-Proadrenomedullin (MR-proADM).
    Zuur-Telgen MC; Citgez E; Zuur AT; VanderValk P; van der Palen J; Kerstjens HAM; Brusse-Keizer M
    COPD; 2021 Dec; 18(6):643-649. PubMed ID: 34886719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stable-State Midrange Proadrenomedullin Is Associated With Severe Exacerbations in COPD.
    Citgez E; Zuur-Telgen M; van der Palen J; van der Valk P; Stolz D; Brusse-Keizer M
    Chest; 2018 Jul; 154(1):51-57. PubMed ID: 29475034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stable State Proadrenomedullin Level in COPD Patients: A Validation Study.
    Zuur-Telgen M; VanderValk P; van der Palen J; Kerstjens HA; Brusse-Keizer M
    COPD; 2017 Apr; 14(2):219-227. PubMed ID: 27880050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adrenomedullin optimises mortality prediction in COPD patients.
    Brusse-Keizer M; Zuur-Telgen M; van der Palen J; VanderValk P; Kerstjens H; Boersma W; Blasi F; Kostikas K; Milenkovic B; Tamm M; Stolz D
    Respir Med; 2015 Jun; 109(6):734-42. PubMed ID: 25937049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term Prognosis in COPD Exacerbation: Role of Biomarkers, Clinical Variables and Exacerbation Type.
    Grolimund E; Kutz A; Marlowe RJ; Vögeli A; Alan M; Christ-Crain M; Thomann R; Falconnier C; Hoess C; Henzen C; Zimmerli W; Mueller B; Schuetz P;
    COPD; 2015 Jun; 12(3):295-305. PubMed ID: 25230352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stable-State Midrange-Proadrenomedullin Level Is a Strong Predictor of Mortality in Patients With COPD.
    Zuur-Telgen MC; Brusse-Keizer MG; VanderValk PD; van der Palen J; Kerstjens HA; Hendrix MG
    Chest; 2014 Mar; 145(3):534-541. PubMed ID: 27845633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Midregion prohormone adrenomedullin and prognosis in patients presenting with acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial.
    Maisel A; Mueller C; Nowak RM; Peacock WF; Ponikowski P; Mockel M; Hogan C; Wu AH; Richards M; Clopton P; Filippatos GS; Di Somma S; Anand I; Ng LL; Daniels LB; Neath SX; Christenson R; Potocki M; McCord J; Hartmann O; Morgenthaler NG; Anker SD
    J Am Coll Cardiol; 2011 Aug; 58(10):1057-67. PubMed ID: 21867843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma pro-adrenomedullin but not plasma pro-endothelin predicts survival in exacerbations of COPD.
    Stolz D; Christ-Crain M; Morgenthaler NG; Miedinger D; Leuppi J; Müller C; Bingisser R; Struck J; Müller B; Tamm M
    Chest; 2008 Aug; 134(2):263-272. PubMed ID: 18490402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mid-regional pro-adrenomedullin in patients with acute dyspnea: Data from the Akershus Cardiac Examination (ACE) 2 Study.
    Pervez MO; Lyngbakken MN; Myhre PL; Brynildsen J; Langsjøen EC; Høiseth AD; Christensen G; Omland T; Røsjø H
    Clin Biochem; 2017 May; 50(7-8):394-400. PubMed ID: 28065681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can mid-regional pro-adrenomedullin (MR-proADM) increase the prognostic accuracy of NEWS in predicting deterioration in patients admitted to hospital with mild to moderately severe illness? A prospective single-centre observational study.
    Graziadio S; O'Leary RA; Stocken DD; Power M; Allen AJ; Simpson AJ; Price DA
    BMJ Open; 2019 Feb; 8(11):e020337. PubMed ID: 30798282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does mid-regional pro-adrenomedullin (MR-proADM) improve the sequential organ failure assessment-score (SOFA score) for mortality-prediction in patients with acute infections? Results of a prospective observational study.
    Haag E; Gregoriano C; Molitor A; Kloter M; Kutz A; Mueller B; Schuetz P
    Clin Chem Lab Med; 2021 May; 59(6):1165-1176. PubMed ID: 33554514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Usefulness of midregional pro-adrenomedullin as a marker of organ damage and predictor of mortality in patients with sepsis.
    Bernal-Morell E; García-Villalba E; Vera MDC; Medina B; Martinez M; Callejo V; Valero S; Cinesi C; Piñera P; Alcaraz A; Marin I; Muñoz A; Cano A
    J Infect; 2018 Mar; 76(3):249-257. PubMed ID: 29246637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thirty and ninety days mortality predictive value of admission and in-hospital procalcitonin and mid-regional pro-adrenomedullin testing in patients with dyspnea. Results from the VERyfing DYspnea trial.
    Travaglino F; Russo V; De Berardinis B; Numeroso F; Catania P; Cervellin G; Nigra SG; Geraci F; Bressan MA; Guerrini S; Cavazza M; Folli C; Monzani V; Battista S; Mengozzi G; Noto P; Carpinteri G; Semplicini A; Stella F; Ingrassia S; Moscatelli P; Giuntini P; Salerno G; Cardelli P; Di Somma S
    Am J Emerg Med; 2014 Apr; 32(4):334-41. PubMed ID: 24559907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mid-regional pro-adrenomedullin in the early evaluation of acute chest pain patients.
    Haaf P; Twerenbold R; Reichlin T; Faoro J; Reiter M; Meune C; Steuer S; Bassetti S; Ziller R; Balmelli C; Campodarve I; Zellweger C; Kilchenmann A; Irfan A; Papassotiriou J; Drexler B; Mueller C
    Int J Cardiol; 2013 Sep; 168(2):1048-55. PubMed ID: 23199555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Usefulness of midregional proadrenomedullin to predict poor outcome in patients with community acquired pneumonia.
    Gordo-Remartínez S; Calderón-Moreno M; Fernández-Herranz J; Castuera-Gil A; Gallego-Alonso-Colmenares M; Puertas-López C; Nuevo-González JA; Sánchez-Sendín D; García-Gámiz M; Sevillano-Fernández JA; Álvarez-Sala LA; Andueza-Lillo JA; de Miguel-Yanes JM
    PLoS One; 2015; 10(6):e0125212. PubMed ID: 26030588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The vasoactive peptide MR-pro-adrenomedullin in COVID-19 patients: an observational study.
    Gregoriano C; Koch D; Kutz A; Haubitz S; Conen A; Bernasconi L; Hammerer-Lercher A; Saeed K; Mueller B; Schuetz P
    Clin Chem Lab Med; 2021 Apr; 59(5):995-1004. PubMed ID: 33554516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Midregional proadrenomedullin as a prognostic tool in community-acquired pneumonia.
    Huang DT; Angus DC; Kellum JA; Pugh NA; Weissfeld LA; Struck J; Delude RL; Rosengart MR; Yealy DM
    Chest; 2009 Sep; 136(3):823-831. PubMed ID: 19363212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endothelium-associated biomarkers mid-regional proadrenomedullin and C-terminal proendothelin-1 have good ability to predict 28-day mortality in critically ill patients with SARS-CoV-2 pneumonia: A prospective cohort study.
    van Oers JAH; Kluiters Y; Bons JAP; de Jongh M; Pouwels S; Ramnarain D; de Lange DW; de Grooth HJ; Girbes ARJ
    J Crit Care; 2021 Dec; 66():173-180. PubMed ID: 34340901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mid-regional proadrenomedullin: An early marker of response in critically ill patients with severe community-acquired pneumonia?
    Pereira JM; Azevedo A; Basílio C; Sousa-Dias C; Mergulhão P; Paiva JA
    Rev Port Pneumol (2006); 2016; 22(6):308-314. PubMed ID: 27160747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MR-Proadrenomedullin as biomarker of renal damage in urinary tract infection in children.
    Peñalver Penedo R; Rupérez Lucas M; Álvarez-Sala Walther LA; Torregrosa Benavent A; Casas Losada ML; Bañuelos Andrio L; Rebolledo Poves AB; Bueno Campaña M
    BMC Pediatr; 2021 Jun; 21(1):292. PubMed ID: 34187408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.